MILREM-ROBOTICS
30.6.2021 09:02:13 CEST | Business Wire | Press release
The consortium behind iMUGS, a 32,6 MEUR project with the aim of developing the European standard unmanned ground system (UGS), demonstrated the results of the first phase of the project – deploying unmanned systems to the battlefield and teaming them with manned units and vehicles. The demonstration was spearheaded by the coordinator of the consortium, Europe’s leading developer of robotics and autonomous systems Milrem Robotics.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210630005046/en/
During iMUGS (integrated Modular Unmanned Ground System) a modular, cyber secure and scalable architecture for hybrid manned-unmanned systems will be developed to standardize a European wide ecosystem for aerial and ground platforms, command, control and communication equipment, sensors, payloads, and algorithms. Addressed operational challenges include enhanced interoperability, increased situational awareness and faster decision-making.
The system will utilize an existing unmanned ground vehicle – Milrem Robotics’ THeMIS – and a specific list of payloads.
"The main objective of the iMUGS project is to integrate robotic systems with existing manned technology into European defence forces adding a new capability that will overmatch our adversaries’ abilities," said Kuldar Väärsi, CEO of Milrem Robotics. He noted that iMUGS will contribute to the strategic autonomy of the European Union and strengthen the cooperation between the member states.
During the first demonstration consortium partners showcased how the THeMIS can be deployed onto the battlefield using common Armoured Personnel Carriers (APC) and teamed with unmanned aerial systems. Specific technology used were the Boxer APC by Krauss-Maffei Wegmann (KMW) and a tethered drone by Acecore Technologies. A multirotor drone by Atlas Dynamics was also part of the scenario.
Altogether two scenarios were played out in cooperation with the Estonian Defence Forces.
In the first scenario the THeMIS integrated with Acecore’s tethered drone was operated Beyond the Line of Sight (BLOS) by the soldiers and used to detect and target an enemy position. After determining the target indirect fire was ordered and after-action review performed using the drone footage.
The purpose of the second scenario was to retrieve a casualty from a crashed vehicle and afterwards retrieve the vehicle. Both actions were performed with the THeMIS UGV while the Boxer towed the UGV into the mission area and Atlas’ drone provided overwatch and situational awareness.
“The demonstration confirmed that we have the interaction between manned and unmanned systems, as well as the interaction of hardware and software, under control,” said Thomas Reining, iMUGS Project Manager in Krauss-Maffei Wegmann.
The requirements for the standardized UGS have been set by seven EU member states: Estonia, the leader of the project, and Belgium, Finland, France, Germany, Latvia, and Spain.
“All of the participating nations have shown great interest in contributing to the development of the European UGS,” said Martin Jõesaar, iMUGS project officer in the Estonian Centre for Defence Investments. “The countries understand that they have to grow with the industry to integrate this kind of new technology rapidly and guide the industry towards the best solutions.”
iMUGS is a cooperation between 13 parties: Milrem Robotics (project coordinator), Talgen Cybersecurity, Safran Electronics & Defense, NEXTER Systems, Krauss-Maffei Wegmann, Diehl Defence, Bittium, Insta DefSec, (Un)Manned, dotOcean, Latvijas Mobilais Telefons, GMV Aerospace and Defence, and Royal Military Academy of Belgium.
Watch the Demo 1 Scenario 1 here - https://youtu.be/wAQHPdmm48M
Watch the Demo 1 Scenario 2 here - https://youtu.be/2vobuDOcfDA
View source version on businesswire.com: https://www.businesswire.com/news/home/20210630005046/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
